Status:
RECRUITING
Axillary Management After Neoadjuvant Chemotherapy
Lead Sponsor:
Medipol University
Conditions:
Breast Cancer
Breast Neoplasms
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
The standard treatment for locally advanced and node-positive breast cancer is surgery following neoadjuvant chemotherapy (NAC). Using NAC in advanced-stage tumors and biologically aggressive subtypes...
Detailed Description
The current study was designed as a prospective randomized clinical trial conducted at two participating centers to evaluate the predictability of sentinel lymph node biopsy (SLNB) using axillary ultr...
Eligibility Criteria
Inclusion
- 18-65 years-old female patients
- Clinical stage T1-3 and biopsy-proven N1 breast cancer
- Axillary nodal involvement
- Volunteer to participate in to study
Exclusion
- A history of axillary surgery or SLNB, prior axillary excisional lymph node surgery,
- N2-3 disease with a decision for initial axillary lymph node dissection (ALND),
- Diagnosis of inflammatory breast cancer,
- Presence of distant metastasis
- Incomplete chemotherapy, pregnancy, and lactation
- T4 tumors
- Refusal to participate in to study
Key Trial Info
Start Date :
March 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 15 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06096545
Start Date
March 12 2024
End Date
August 15 2024
Last Update
March 13 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Medipol University Hospital
Istanbul, Bagcilar, Turkey (Türkiye), 34083
2
Istanbul Gaziosmanpasa Training and Research Hospital
Istanbul, Turkey (Türkiye), 34083